KDventures AB 

€0
0
-€0.01-99.07% Today

Statistics

Day High
0.01
Day Low
0
52W High
0.09
52W Low
0
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2I9.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
BridgeBio Pharma
BBIO
Mkt Cap14.21B
BridgeBio Pharma focuses on genetic diseases and targeted therapies, similar to Karolinska Development's investment in biotech and pharmaceutical companies.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.45B
Vertex Pharmaceuticals is involved in creating transformative medicines for serious diseases, paralleling Karolinska's focus on high-impact medical conditions.
Sarepta Therapeutics
SRPT
Mkt Cap2.13B
Sarepta Therapeutics specializes in precision genetic medicine, competing in the same innovative biotechnology space as Karolinska Development.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.28B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, similar to Karolinska's strategy in life sciences investments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap40.77B
Alnylam Pharmaceuticals works on RNAi therapeutics, a cutting-edge approach in biotech where Karolinska Development also invests.
CRISPR Therapeutics
CRSP
Mkt Cap4.7B
CRISPR Therapeutics is a leader in gene editing technology, a field relevant to Karolinska Development's interest in groundbreaking medical technologies.
Novo Nordisk
NVO
Mkt Cap182.6B
Novo Nordisk is a global healthcare company with a focus on innovative treatments for diabetes and other serious chronic conditions, aligning with Karolinska's investment focus.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.46B
Regeneron Pharmaceuticals is known for its scientific capabilities in biopharmaceuticals, directly competing with Karolinska's portfolio companies.
Bio-Techne
TECH
Mkt Cap8.48B
Bio-Techne develops, manufactures, and sells biotechnology products and clinical diagnostic controls, overlapping with Karolinska's biotech interests.

About

Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark. It prefers to be a lead investor in its portfolio companies however does consider co-investments also. It seeks to invest in up to five projects annually. Karolinska Development AB (publ) was founded in 2003 and is headquartered in Stockholm, Sweden.
Show more...
CEO
Dr. Viktor Drvota M.D., Ph.D.
Employees
8
Country
Sweden
ISIN
SE0002190926

Listings

0 Comments

Share your thoughts

FAQ

What is KDventures AB stock price today?
The current price of 2I9.STU is €0 EUR — it has decreased by -99.07% in the past 24 hours. Watch KDventures AB stock price performance more closely on the chart.
What is KDventures AB stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange KDventures AB stocks are traded under the ticker 2I9.STU.
Is KDventures AB stock price growing?
2I9.STU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year KDventures AB has showed a -99.86% decrease.
How many employees does KDventures AB have?
As of April 29, 2026, the company has 8 employees.
In which sector is KDventures AB located?
KDventures AB operates in the Health & Wellness sector.
When did KDventures AB complete a stock split?
KDventures AB has not had any recent stock splits.
Where is KDventures AB headquartered?
KDventures AB is headquartered in Solna, Sweden.